Recommendations regarding which patients should be considered for allogeneic stem cell transplantation
| High-risk features indicating the need to initiate a donor search for transplant-eligible patients . |
|---|
| The presence of specific cytogenetic abnormalities at diagnosis or acquisition while on therapy, including • Isochromosome 17q • 3q26.2 • Monosomy 7/7q- • Complex karyotype |
| Failure to achieve any cytogenetic or molecular response to 2G-TKI after a minimum of 3 months of therapy |
| Recurrent grade IV cytopenias despite TKI dose interruptions, dose modifications, and cytokine support, especially within the first 3 months of therapy, leading to EMR failure or ELN-defined treatment failure |
| Recurrent grade 4 toxicity preventing consistent TKI dose intensity, resulting in EMR failure or ELN-defined treatment failure on 2 or more lines of TKI therapy |
| Compound kinase domain mutations involving T315I |
| Lymphoblasts >5% at diagnosis |
| High-risk features indicating the need to initiate a donor search for transplant-eligible patients . |
|---|
| The presence of specific cytogenetic abnormalities at diagnosis or acquisition while on therapy, including • Isochromosome 17q • 3q26.2 • Monosomy 7/7q- • Complex karyotype |
| Failure to achieve any cytogenetic or molecular response to 2G-TKI after a minimum of 3 months of therapy |
| Recurrent grade IV cytopenias despite TKI dose interruptions, dose modifications, and cytokine support, especially within the first 3 months of therapy, leading to EMR failure or ELN-defined treatment failure |
| Recurrent grade 4 toxicity preventing consistent TKI dose intensity, resulting in EMR failure or ELN-defined treatment failure on 2 or more lines of TKI therapy |
| Compound kinase domain mutations involving T315I |
| Lymphoblasts >5% at diagnosis |
ELN, European LeukemiaNet; EMR, early molecular response.